Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$274K Sell
3,909
-311
-7% -$16.1K 0.01% 444
2026
Q1
$214K Buy
+4,220
New +$197K ﹤0.01% 411
2024
Q3
Sell
-2,791
Closed -$331K 401
2024
Q2
$331K Buy
2,791
+40
+1% +$5.06K 0.01% 304
2024
Q1
$293K Hold
2,751
0.01% 317
2023
Q4
$274K Buy
+2,751
New +$231K 0.01% 301

Other funds holding MRNA

AlTi Global's MRNA Position: Q2 2026 in Review

AlTi Global reduced its Moderna (MRNA) stake by 7.4% in Q2 2026, selling an estimated $16.1K and leaving 3,909 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #444.

AlTi Global first reported a position in MRNA in Q4 2023 and has held it in 5 quarters since. The position peaked at $331K in Q2 2024. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • AlTi Global held 3,909 shares of Moderna worth $274K as of Q2 2026.
  • AlTi Global sold 311 Moderna shares in Q2 2026, an estimated $16.1K.
  • Moderna made up 0.01% of AlTi Global's portfolio in Q2 2026, its #444 holding.
  • AlTi Global first reported a position in Moderna in Q4 2023 and has held it in 5 quarters since.
  • AlTi Global's Moderna position peaked at $331K in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on AlTi Global's 13F filing for Q2 2026, filed 5 Aug 2026.